Conclusions:
Age, ibrutinib dose, E/e’, and PALS on pre-treatment echocardiogram were significantly associated with the development of IRAF. On multivariate regression analysis, age, PALS and PACS remained significantly associated with the development of IRAF. PALS may demonstrate an age-dependent association with IRAF, whereas PACS may represent age-independent loss of atrial contraction. Future studies are needed to determine if this information can identify increased risk of IRAF, need for enhanced surveillance, adjustment in anticoagulation management, and possibly alternate oncologic therapies.